| Functional annotation of ESR1 gene fusions in estrogen receptor-positive breast cancer JT Lei, J Shao, J Zhang, M Iglesia, DW Chan, J Cao, M Anurag, P Singh, ... Cell reports 24 (6), 1434-1444. e7, 2018 | 95 | 2018 |
| Comprehensive profiling of DNA repair defects in breast cancer identifies a novel class of endocrine therapy resistance drivers M Anurag, N Punturi, J Hoog, MN Bainbridge, MJ Ellis, S Haricharan Clinical Cancer Research 24 (19), 4887-4899, 2018 | 77 | 2018 |
| Loss of MutL disrupts CHK2-dependent cell-cycle control through CDK4/6 to promote intrinsic endocrine therapy resistance in primary breast cancer S Haricharan, N Punturi, P Singh, KR Holloway, M Anurag, J Schmelz, ... Cancer discovery 7 (10), 1168-1183, 2017 | 75 | 2017 |
| Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer NB Punturi, S Seker, V Devarakonda, A Mazumder, R Kalra, CH Chen, ... Nature communications 12 (1), 2940, 2021 | 15 | 2021 |
| Emerging target discovery and drug repurposing opportunities in chordoma DM Freed, J Sommer, N Punturi Frontiers in Oncology 12, 1009193, 2022 | 3 | 2022 |
| Molecular portraits of cell cycle checkpoint kinases in cancer evolution, progression, and treatment responsiveness E Oropeza, S Seker, S Carrel, A Mazumder, D Lozano, A Jimenez, ... Science Advances 9 (26), eadf2860, 2023 | 1 | 2023 |
| Abstract P4-04-01: Loss of mismatch repair predicts resistance to endocrine therapy and sensitivity to CDK4/6 inhibitors in ER+ breast cancer S Haricharan, N Punturi, P Singh, KR Holloway, M Anurag, J Schmelz, ... Cancer Research 78 (4_Supplement), P4-04-01-P4-04-01, 2018 | 1 | 2018 |
| Subcellular MLH1 protein as first in class biomarker for CDK4/6 response in endocrine resistant ER+/HER2-breast cancer A Mazumder, E Oropeza, N Punturi, S Haricharan Cancer Research 84 (6_Supplement), 5129-5129, 2024 | | 2024 |
| Abstract B021: Assessing replication stress as an actionable therapeutic opportunity in chordoma N Punturi, W Leung, J Levy, L Zou, GM Cote, DM Freed Cancer Research 84 (1_Supplement), B021-B021, 2024 | | 2024 |
| Aberrant subcellular localization of mismatch repair protein MLH1 dysregulates the cell cycle to create new therapeutic opportunities S Haricharan, A Mazumder, T DeWitt, E Oropeza, N Punturi, D Lozano, ... bioRxiv, 2024.02. 27.582389, 2024 | | 2024 |
| Assessing replication stress as an actionable therapeutic opportunity in chordoma N Punturi, L Dolat, W Leung, J Levy, L Zou, DM Freed, GM Cote Cancer Research 83 (7_Supplement), 6195-6195, 2023 | | 2023 |
| Mechanisms of EGFR inhibitor sensitivity and resistance in chordoma N Punturi, L Dolat, J Levy, J Sommer, DM Freed Cancer Research 83 (7_Supplement), 4865-4865, 2023 | | 2023 |
| Abstract P3-10-02: Cell cycle dysregulation in breast cancer: why the details matter S Seker, E Oropeza, S Carrel, A Mazumder, N Punturi, J Lei, M Anurag, ... Cancer Research 83 (5_Supplement), P3-10-02-P3-10-02, 2023 | | 2023 |
| Abstract PD8-05: Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer S Haricharan, N Punturi, S Seker, V Devarakonda, R Kalra, CH Chen, ... Cancer Research 81 (4_Supplement), PD8-05-PD8-05, 2021 | | 2021 |
| Differential impact of mutations in cell cycle checkpoint kinases on breast cancer presentation and prognosis S Seker, NB Punturi, S Carell, AM Mazumder, N Fusco, MN Bainbridge, ... bioRxiv, 2020.10. 29.361352, 2020 | | 2020 |
| Using mutations in mismatch repair genes to predict response to palbociclib A Mazumder, N Punturi, S Khanal, A Jimenez, S Haricharan Clinical Cancer Research 26 (12_Supplement_1), 23-23, 2020 | | 2020 |
| Defects in multiple DNA damage repair pathways render endocrine treatment resistance in ER+ breast cancer patients M Anurag, N Punturi, J Hoog, MN Bainbridge, MJ Ellis, S Haricharan Cancer Research 78 (13_Supplement), 917-917, 2018 | | 2018 |
| Functional and therapeutic significance of ESR1 gene fusions in breast cancer JT Lei, J Shao, J Zhang, M Iglesia, DW Chan, J Cao, M Anurag, P Singh, ... Cancer Research 78 (13_Supplement), 5240-5240, 2018 | | 2018 |
